PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer
PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer Stocktwits
Covered in this story
What has happened since
- Pfizer is up 6.3% since this was published, 8 days ago.
- Lilly (Eli) is up 7.5% since this was published, 8 days ago.
- Merck & Co. is up 2.5% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Cantor Fitzgerald’s $1.44k target on $LLY is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Cantor Fitzgerald’s track record →Analyst targets on Pfizer
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 47 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Stocktwits's public RSS feed. The full reporting belongs to Stocktwits — please read it on their site.